Evolus, Inc. announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau® (prabotulinumtoxinA-xvfs) for the treatment of moderate to severe glabellar lines in adult patients. The " extra-strength" glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction. The study has three arms: Jeuveau® Extra- strength 40U and two active controls, BOTOX 20U and Jeuveau 20U.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.42 USD | -1.25% | +6.42% | +27.45% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.45% | 840M | |
+34.35% | 705B | |
+30.71% | 583B | |
-3.49% | 364B | |
+20.15% | 332B | |
+6.19% | 291B | |
+15.80% | 238B | |
-3.44% | 210B | |
+10.43% | 209B | |
+9.21% | 169B |
- Stock Market
- Equities
- EOLS Stock
- News Evolus, Inc.
- Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau